These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 25090648

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Dynamic profiles of neutralizing antibody responses elicited in rhesus monkeys immunized with a combined tetravalent DTaP-Sabin IPV candidate vaccine.
    Sun M, Ma Y, Xu Y, Yang H, Shi L, Che Y, Liao G, Jiang S, Zhang S, Li Q.
    Vaccine; 2014 Feb 19; 32(9):1100-6. PubMed ID: 24412578
    [Abstract] [Full Text] [Related]

  • 3. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
    Crawt L, Atkinson E, Tedcastle A, Pegg E, sIPV Study Group, Minor P, Cooper G, Rigsby P, Martin J.
    J Infect Dis; 2020 Feb 03; 221(4):544-552. PubMed ID: 30788503
    [Abstract] [Full Text] [Related]

  • 4. [Immunogenicity of sabin inactivated poliovirus vaccine induced by diphtheria-tetanus-acellular pertussis and Sabin inactivated poliovirus combined vaccine].
    Ma Y, Qin M, Hu HQ, Ji G, Feng L, Gao N, Gu J, Xie BF, He JH, Sun MB.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Jun 03; 25(3):197-200. PubMed ID: 21977591
    [Abstract] [Full Text] [Related]

  • 5. Effects of the thermal denaturation of Sabin-derived inactivated polio vaccines on the D-antigenicity and the immunogenicity in rats.
    Murakami K, Fujii Y, Someya Y.
    Vaccine; 2020 Apr 09; 38(17):3295-3299. PubMed ID: 32197923
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The progress of postapproval clinical studies on Sabin IPV.
    Shi L, Sun M.
    Hum Vaccin Immunother; 2022 Dec 31; 18(1):1-4. PubMed ID: 34213408
    [Abstract] [Full Text] [Related]

  • 12. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: a phase I trial in healthy adults.
    Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA.
    Vaccine; 2013 Nov 12; 31(47):5531-6. PubMed ID: 24063976
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.
    Shimizu H.
    Vaccine; 2016 Apr 07; 34(16):1975-85. PubMed ID: 25448090
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.
    Thomassen YE, van 't Oever AG, van Oijen MG, Wijffels RH, van der Pol LA, Bakker WA.
    PLoS One; 2013 Apr 07; 8(12):e83374. PubMed ID: 24349497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.